Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35926811)

  • 1. CDX2 expression in primary skin tumors-case series and review of the literature.
    Tekin B; Kundert P; Yang HH; Guo R
    Hum Pathol; 2022 Nov; 129():1-10. PubMed ID: 35926811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's Disease.
    Lora V; Kanitakis J
    Anticancer Res; 2009 Dec; 29(12):5033-7. PubMed ID: 20044613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2 and LEF-1 expression in pilomatrical tumors and their utility in the diagnosis of pilomatrical carcinoma.
    Tumminello K; Hosler GA
    J Cutan Pathol; 2018 May; 45(5):318-324. PubMed ID: 29369390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDX2 and SATB2 positivity in pilomatrix carcinoma: Avoiding an erroneous diagnosis of cutaneous metastasis of gastrointestinal origin.
    Kenny B; Osmond A
    J Cutan Pathol; 2022 Apr; 49(4):399-402. PubMed ID: 34797586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CDX2 and Thyroid Transcription Factor-1 in Oropharyngeal Undifferentiated Carcinomas: A Potential Diagnostic Pitfall.
    Chernock RD; Bibbey S; El-Mofty SK; Carpenter DH; Lewis JS
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):268-273. PubMed ID: 27389559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
    De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
    Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case of Biphenotypic Adnexal Carcinoma With Bowenoid and Basaloid Features: Focus on the Expression of SOX9 and Wnt Signaling Pathway Molecules, Including CDX2.
    Sugimoto A; Fujimoto M; Masuo Y; Nakagawa Y; Yamada Y; Kono F; Haga H
    Am J Dermatopathol; 2023 Dec; 45(12):835-838. PubMed ID: 37883950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
    Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
    Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
    Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
    Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
    Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
    Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of CDX2 is highly antibody dependant.
    Borrisholt M; Nielsen S; Vyberg M
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):64-72. PubMed ID: 22595949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic differences between intestinal-type and low-grade papillary sinonasal adenocarcinomas: an immunohistochemical study of 22 cases utilizing CDX2 and MUC2.
    Cathro HP; Mills SE
    Am J Surg Pathol; 2004 Aug; 28(8):1026-32. PubMed ID: 15252308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
    Bayrak R; Haltas H; Yenidunya S
    Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.
    Winn B; Tavares R; Fanion J; Noble L; Gao J; Sabo E; Resnick MB
    Hum Pathol; 2009 Mar; 40(3):398-404. PubMed ID: 18992917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules.
    Lee MJ; Vogt AP; Hsiao W; Osunkoya AO
    Tumour Biol; 2012 Dec; 33(6):2185-8. PubMed ID: 22895825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
    Landau MS; Kuan SF; Chiosea S; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
    Werling RW; Yaziji H; Bacchi CE; Gown AM
    Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
    Jaffee IM; Rahmani M; Singhal MG; Younes M
    Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.